US FDA approves Rybrevant plus chemotherapy to treat EGFR mutated NSCLC
The FDA approval is based on results from the Phase 3 PAPILLON study, which showed Rybrevant plus chemotherapy…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Mar 24
The FDA approval is based on results from the Phase 3 PAPILLON study, which showed Rybrevant plus chemotherapy…
01 Mar 24
Abrysvo bivalent RSV vaccine showed 77.8% efficacy against RSV-associated LRTD after disease surveillance in season two, and 88.9%…
29 Feb 24
Ginkgo Bioworks has acquired synthetic biology company Patch Biosciences, pharmaceutical company Reverie Labs, and CRISPR-based diagnostic test developer…
29 Feb 24
Under the global licence and collaboration agreement, both firms will advance the French biotech’s OSE-230 to treat chronic…
29 Feb 24
Under the agreement, Viatris will get exclusive global development and commercialisation rights to these assets along with the…
29 Feb 24
Agreement spans wide range of Medidata’s solutions to enhance clinical trial efficiency
28 Feb 24
Biological E will manufacture up to 50 million doses of the Qdenga vaccine annually, advancing Takeda’s ability to…
28 Feb 24
Proceeds from the financing are expected to be used to support Denali’s ongoing research and development activities, the…
27 Feb 24
Neomorph will receive upfront and near-term milestone payments, R&D funding, and milestone payments, totalling $1.46bn from Novo Nordisk,…
27 Feb 24
The approval allows the oral suspension to be utilised in treating CLL/ SLL, WM, and cGVHD following the…